Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models

Rachel M. Squillace(Ariadne Diagnostics (United States)), Victor M. Rivera(Ariadne Diagnostics (United States))
International Journal of Oncology
May 18, 2012
10.3892/ijo.2012.1487
Cited by 31

Related Papers

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
|Clinical Cancer Research|2016|325
The utility of MRI in suspected MS [RETIRED]
|Neurology|2003|190
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
|Blood|2016|65
Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
|Unknown|2023|0